Medicine guide
Zurampic
·
- Prescription status not stated
- Muscles, joints and bones
- Active substance
- Lesinurad
- Used in
- Muscles, joints and bones
- Made by
- Grünenthal GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Grünenthal GmbH |
|---|---|
| Active substance | Lesinurad |
| Used in | Muscles, joints and bones |
| Classification | M04AB05 · Muscles, joints and bones |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2016-02-18 |
| Last updated by the regulator | 2020-07-31 |
| EMA product number | EMEA/H/C/003932 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).